| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968304 | Vaccine | 2011 | 9 Pages |
Abstract
⺠We evaluated the cost-effectiveness of pneumococcal vaccines, PHiD-CV and PCV-13. ⺠We estimated both vaccines reduced disease compared with the current PCV-7 program. ⺠Additional benefits for PHiD-CV were primarily due to prevention of otitis media. ⺠Additional benefits for PCV-13 were primarily due to prevention of invasive disease. ⺠The relative cost-effectiveness was uncertain and dependent on key assumptions.
Keywords
ICERPCV-13PHiD-CVNTHiPCV-7QALYIPDOPAcDNANon-typeable Haemophilus influenzaeCost-effectivenessEconomic evaluationAustraliaStreptococcus pneumoniaeOtitis mediadisease burdenInvasive pneumococcal diseaseCommunity acquired pneumoniaICDBeachInternational Classification of DiseasesPneumococcal infectionOpsonophagocytic activity7-valent pneumococcal conjugate vaccinePneumococcal conjugate vaccine13-Valent pneumococcal conjugate vaccinePCVVaccine efficacyCaPquality adjusted life year
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Anthony T. Newall, Prudence Creighton, David J. Philp, James G. Wood, C. Raina MacIntyre,